AVBP
ArriVent BioPharma, Inc. Common StockHealthcare·Biotechnology
$30.27
$1.4B market cap
Revenue
$0.0M
Free Cash Flow
$-72.5M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3
2-Year Price History
$26.73+37.7%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -46.1 | -46.1 | -43.3 | -41.9 | -41.9 | -0.0 | 326.4 | 0.4 | 45.1 | -159.7% | -- | -- |
| Act | 2025-Q4 | 0.0 | -38.8 | -38.8 | -35.5 | -30.7 | -30.7 | -0.0 | 312.8 | 0.0 | 38.5 | -155.5% | -- | -- |
Valuation & Metrics
Market Stats
Price$30.27
Market Cap$1.4B
Enterprise Value$1.1B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-5.1%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-78.9M
Free Cash Flow$-72.5M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-157.6%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares7.1M
Days to Cover14.3
Change (vs Prior)-7.3%
Need at least 2 settlement dates for chart
Employees
Headcount52
Revenue / Employee$0
Gross Profit / Employee$0
Cash Runway
54.0months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
63.5%(+28.6% YoY)
121 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
13.1%(+5.4% YoY)
11 filers
Vanguard, iShares, SPDR
Market makers
0.2%(+0.1% YoY)
6 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | $102M | $20.42 | +$6.8M | +$47.6M | -9.0% | $3.69B |
| INFINITUM ASSET MANAGEMENT, LLC | $95.7M | $22.91 | +$577K | +$48.0M | +1.2% | $799M |
| HHLR ADVISORS, LTD. | $90.6M | $17.95 | +$0 | −$12.8M | -1.5% | $1.67B |
| ORBIMED ADVISORS LLC | $69.8M | $17.86 | +$0 | +$0 | -8.1% | $4.38B |
| FMR LLC | $69.6M | $18.50 | −$15.9M | +$21.6M | -0.0% | $1.89T |
| BlackRock, Inc.Passive | $58.4M | $22.93 | +$3.6M | +$9.0M | -0.2% | $5.69T |
| Octagon Capital Advisors LP | $45.5M | $18.63 | +$0 | −$2.0M | +1.0% | $904M |
| Novo Holdings A/S | $44.8M | $18.23 | +$0 | +$1.6M | -3.2% | $1.23B |
| Sofinnova Investments, Inc. | $39.1M | $17.86 | +$0 | +$0 | +2.7% | $1.94B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $35.3M | $23.07 | +$35.3M | +$35.3M | — | $4.04T |
| General Catalyst Group Management, LLC | $34.5M | $17.86 | +$0 | +$0 | -3.1% | $184M |
| STATE STREET CORPPassive | $32.8M | $22.43 | +$7.6M | +$15.1M | -0.2% | $2.89T |
| Vivo Capital, LLC | $20.4M | $23.07 | +$20.4M | +$20.4M | -7.0% | $1.20B |
| GOLDMAN SACHS GROUP INC | $19.7M | $21.88 | +$2.6M | +$17.9M | -0.2% | $760.93B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $18.5M | $20.87 | +$1.2M | +$4.4M | +2.3% | $1.61T |
| Point72 Asset Management, L.P. | $17.3M | $22.13 | +$12.3M | +$17.3M | +0.9% | $54.88B |
| HSG Holding Ltd | $14.0M | $17.86 | +$0 | +$0 | -2.4% | $1.62B |
| Fund 1 Investments, LLC | $11.5M | $21.28 | −$1.5M | +$11.5M | -3.8% | $767M |
| UBS Group AG | $11.2M | $19.44 | +$815K | +$6.6M | -0.3% | $562.11B |
| BALYASNY ASSET MANAGEMENT LLC | $9.8M | $22.83 | +$8.8M | +$9.8M | -0.4% | $48.01B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-2.31%
avg per quarter
Holders (ex-self)
-2.18%
excl. this stock
Buyers (this Q)
-1.83%
88 buyers · $0.20B in
Sellers (this Q)
-0.03%
32 sellers · $0.02B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+41.3%
how holders react when this stock falls
On quiet Qs
+16.7%
−10% to +10% baseline
On rallies (+10%+)
+19.6%
how they react when this stock rises
Holders' portfolio flow this Q
-2.0%
outflows — trims may be forced
Sellers' portfolio flow this Q
+3.9%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-0.7%
Holder mid (any stock)
-3.8%
Holder rally (any stock)
-7.1%
Biggest decreases this quarter
FMR LLC−$15.9Mα-0.0AIHC Capital Management Ltdexited−$13.0MRosalind Advisors, Inc.exited−$4.3MHidden Lake Asset Management LPexited−$3.1MFund 1 Investments, LLC−$1.5Mα-3.8SIMPLEX TRADING, LLCexited−$917KAnson Funds Management LPexited−$712KNEOS Investment Management LLCexited−$654KTEMA ETFS LLCexited−$644KWalleye Capital LLCexited−$445K
New buyers this quarter
Top-5 holders · 44.1%
SUVRETTA CAPITAL MANAGEMENT, LLC--
INFINITUM ASSET MANAGEMENT, LLC--
HHLR ADVISORS, LTD.--
ORBIMED ADVISORS LLC--
FMR LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
HHLR ADVISORS, LTD.3.9MSUVRETTA CAPITAL MANAGEMENT, LLC4.4MINFINITUM ASSET MANAGEMENT, LLC4.1MORBIMED ADVISORS LLC3.0MFMR LLC3.0MOctagon Capital Advisors LP2.0MSofinnova Investments, Inc.1.7MNovo Holdings A/S1.9MGeneral Catalyst Group Management, LLC1.5MVivo Capital, LLC886K
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Year (3 analysts)$40.333320.0%
Current Price$30.27
Analyst Ratings
6
Buy: 6Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$12.98M
1 txn · 1 insider · 555,555 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2025-12-10 | SELL | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 555,555 | $23.37 | $12.98M | $91.82M |
Order Flow (FINRA, ~3w lag)
13.4%retail+3.3pp
22.9%dark-1.8pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
ArriVent BioPharma: The High-Octane Dilution Machine
Overall Risk
7/10
Fraud
2/10
Dilution
9/10
Insolvency
5/10
Earnings Overstated
2/10
Hidden Liabilities
6/10
Legal
3/10
Audit Warnings
2/10
Hidden Upside
6/10
Contextually Acceptable
9/10